FDA MAP
  • Home
  • Training
    • WORKSHOPS
    • WEBINARS
    • CUSTOM TRAINING
  • SERVICES
    • REGULATORY SERVICES
    • FDA AUDITING
    • QUALITY ASSURANCE
    • CLINICAL TRIAL SERVICES
  • News Releases
  • About Us
Real World Data for Animal Drugs, Too: New FDA Guidance Provides Tips
(Thursday, October 21, 2021)
Just like human drugs, animal drugs can also be approved based on real world evidence available from veterinary records. However, there are several issues to be considered for creating sufficient supportive real world data for animal drug approval applications. A new FDA guidance released this week discusses the nuances of the real world data (RWD) expected for veterinary drugs and the real world evidence (RWE) generated from it, and it looks very similar to the advice provided for using RWD/RWE for human drugs. The guidance provides several considerations for data collection, cleaning, analysis, and presentation for productive interactions with the FDA regarding new drugs and new applications for previously approved drugs. For the RWD, FDA expects at the minimum a written description of the protocols used for data collection and transformation to databases, and procedures used to ensure completeness, consistency, and accuracy of data collected. RWE generated using well controlled methods can be used to justify a dose and dosage regimen, indications, develop historical, external, or concurrent controls, justify sample sizes for clinical trials, define appropriate enrollment criteria, and provide the rationale for the endpoints in clinical studies with new veterinary drugs. FDA would accept RWE generated such way for both INADA applications (investigational new animal drug applications) or to provide substantial evidence of effectiveness for an original or supplemental New Animal Drug Approval (NADA) applications. The guidance establishes almost identical expectations from RWD/RWE for animal drugs as have been described previously for human drugs. In general, FDA is consistent in its assertion for the quality of data requirements for all products intended for humans or animals.

Picture
AUTHOR               

 Dr. Mukesh Kumar
​ Founder & CEO, FDAMap


 Email: mkumar@fdamap.com
​ Linkedin: Mukesh Kumar, PhD, RAC
 Instagram: 
mukeshkumarrac 
                           Twitter: @FDA_MAP
                           Youtube: MukeshKumarFDAMap

​

    Newsletter Signup
    Subscribe to FDAMap Newsletter for Refreshing Outlook on Regulatory Topics

Submit

Our Services

  • Workshops
  • Webinars
  • On-Demand Webinars
  • Custom training
  • Training Subscriptions
  • Corporate Registration
  • Certification Program
  • Smart Recruitment
  • Corporate Registration - Online Workshop​

Company

  • About Us​
  • Testimonials
  • Free Resources
  • Newsletter
  • Videos (Free Tutorials)

Support

  • Contact Us
  • Terms of Service
  • Privacy Policy
  • News Archive
Consultation Service
FDA Training Company
Copyright © 2022 FDAMap.com
Use of this Web site constitutes acceptance of the FDAMap Terms of Use and Privacy Policy.